market folly

Seth Klarman's Baupost Group recently filed an amended 13G with the SEC regarding shares of Syneron Medical (ELOS). Per portfolio activity on June 30th, Baupost Group has disclosed a 11.06% ownership stake in ELOS with 3,836,071 shares.

This marks a 155% increase in their position size as they only owned 1,500,000 shares back on March 31st. So while Baupost added to this position significantly, keep in mind that it's still a relatively small equity position for them. Not to mention, Baupost has under 10% of its assets under management allocated long US equities.

In other disclosures from the hedge fund, we saw that Baupost trimmed its Audiovox stake (VOXX) and we also detailed their position in Gabriel Resources (TSE:GBU) as well.

Per Google Finance, Syneron Medical "designs, develops and markets aesthetic medical products based on its various technologies including its Electro-Optical Synergy (ELOS), technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments. The Company’s products, which it sells primarily to physicians and other practitioners, target a range of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment treatment of leg veins and treatment for the temporary reduction in the appearance of cellulite."